These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20598199)

  • 1. New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation.
    de Medina FS; Daddaoua A; Requena P; Capitán-Cañadas F; Zarzuelo A; Dolores Suárez M; Martínez-Augustin O
    Proc Nutr Soc; 2010 Aug; 69(3):454-62. PubMed ID: 20598199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milk-derived proteins and peptides of potential therapeutic and nutritive value.
    Zimecki M; Kruzel ML
    J Exp Ther Oncol; 2007; 6(2):89-106. PubMed ID: 17407968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
    Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
    Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-weaning effects of milk and milk components on the intestinal mucosa in inflammation.
    Russ A; Barnett M; McNabb W; Anderson R; Reynolds G; Roy N
    Mutat Res; 2010 Aug; 690(1-2):64-70. PubMed ID: 20036674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
    Nakase H; Okazaki K; Tabata Y; Chiba T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.
    Ihara S; Hirata Y; Koike K
    J Gastroenterol; 2017 Jul; 52(7):777-787. PubMed ID: 28534191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
    Hering NA; Schulzke JD
    Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
    Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
    Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of systemic and local inflammation with transforming growth factor beta containing formulas.
    Fell JM
    JPEN J Parenter Enteral Nutr; 2005; 29(4 Suppl):S126-8; discussion S129-33, S184-8. PubMed ID: 15980274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
    Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
    Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of carbon monoxide for inflammatory bowel disease.
    Takagi T; Uchiyama K; Naito Y
    Digestion; 2015; 91(1):13-8. PubMed ID: 25632911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
    Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
    Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
    Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
    J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting T-cell migration in inflammatory bowel disease.
    Marsal J; Agace WW
    J Intern Med; 2012 Nov; 272(5):411-29. PubMed ID: 22946654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Casein hydrolysate generated by the cell envelope-associated proteinase of Lactobacillus delbrueckii ssp. lactis CRL 581 protects against trinitrobenzene sulfonic acid-induced colitis in mice.
    Espeche Turbay MB; de Moreno de LeBlanc A; Perdigón G; Savoy de Giori G; Hebert EM
    J Dairy Sci; 2012 Mar; 95(3):1108-18. PubMed ID: 22365194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis.
    Vallance BA; Gunawan MI; Hewlett B; Bercik P; Van Kampen C; Galeazzi F; Sime PJ; Gauldie J; Collins SM
    Am J Physiol Gastrointest Liver Physiol; 2005 Jul; 289(1):G116-28. PubMed ID: 15778431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.